• About Us
    • What We Do
    • Our Story
    • Meet Our Team
  • Products
    • COVID-19 Response
      • COVID-19 Home Test
      • QIAreach COVID
      • ellume·lab COVID Tests
      • Swab+Drop COVID Self-Swab Kit
    • Consumer Products
      • COVID-19 Home Test
      • Influenza Home Test
    • Professional Products
      • ellume·lab
      • Swab+Drop Self-Swab Kit
    • Global Public Health Solutions
      • COVID-19
      • Tuberculosis
      • Pandemic Influenza
  • Our Tech
  • News
    • Corporate Announcements
    • Media
  • Careers
    • Australia
    • United States
  • Contact
  • About Us
    • What We Do
    • Our Story
    • Meet Our Team
  • Products
    • COVID-19 Response
      • COVID-19 Home Test
      • QIAreach COVID
      • ellume·lab COVID Tests
      • Swab+Drop COVID Self-Swab Kit
    • Consumer Products
      • COVID-19 Home Test
      • Influenza Home Test
    • Professional Products
      • ellume·lab
      • Swab+Drop Self-Swab Kit
    • Global Public Health Solutions
      • COVID-19
      • Tuberculosis
      • Pandemic Influenza
  • Our Tech
  • News
    • Corporate Announcements
    • Media
  • Careers
    • Australia
    • United States
  • Contact
World TB Day 2020

World TB Day 2020

#ItsTimeToEndTB: Diagnostics are critical in infectious disease control

Written by Dr Sean Parsons, CEO Ellume.

As the world rallies to curb the spread of COVID-19, this year’s World Tuberculosis Day serves as a stark reminder that the two major biological threats to humans are pandemic viruses (like COVID-19) and tuberculosis (TB) – especially multi-drug resistant TB.

We at Ellume are doing our part in responding to COVID-19 (major announcements to come shortly), but when the COVID threat has eventually passed, we must not forget that we must continue the fight against TB.

On this day 118 years ago, Dr Robert Koch successfully identified the bacteria responsible for causing TB, paving the way for the prevention and control of this deadly disease. It was an important breakthrough in combating a disease that was once one of the most urgent health problems facing the world. Yet a century later with a death rate of 1.5 million people every year, more people will die today from TB than COVID-19.

We all now appreciate that diagnostics are crucial in responding to pandemic viruses, but they are also the key for responding to TB.

At Ellume, our diagnostics platform means we haven an important role to play in the fight against these common infectious diseases. By combining our technology with QIAGEN’s market leading test we have created QuantiFERON® TB Access, an accurate, rapid diagnostic designed for use in moderate and high burden countries. It has the ability to diagnose cases with greater speed and accuracy and overcome the limitations of a lack of infrastructure and shortage of trained technicians. The product can perform up to eight non-invasive tests simultaneously without computer access or a continuous power supply. Together with QIAGEN we are striving to make QuantiFERON® TB Access available later this year.

While we have a long way to go until TB is eradicated, we’re proud that our technology holds the key to bringing faster and more accurate diagnostics to the people who need it most.

#ItsTimeToEndTB

#EndTB #WorldTBDay

Learn about QuantiFERON-Access here.
Learn about Ellume here.

Recent Posts
  • QIAGEN receives U.S. FDA emergency use authorization for rapid portable SARS-CoV-2 antigen test
  • Push to allow at-home COVID tests in Australia
  • Why Aussie startup Ellume’s home-testing tech should help us in the COVID-19 recovery, but can’t
  • An Australian firm producing home COVID-19 tests for the US market has called on the federal government to reconsider its ban
  • Rapid COVID-19 Testing Device, Sunrise Interview with Ellume CEO Dr Sean Parsons
Archives
Categories
Business

Ellume appoints Joanne Moss to its Board as Non-executive Director

Previous thumb

Ellume announces global partnership with QIAGEN for COVID-19 diagnosis

Next thumb
Scroll
ellume logo white
Menu

Home
About Us
COVID-19 Response
Consumer Products
Professional Products
Global Public Health Solutions
Our Tech
News

Quick Links

Contact Us
Terms of Use
Privacy Policy
Whistleblower Policy

Some Ellume products are pending regulatory clearance. © Ellume Limited 2021
ABN 13 141 767 660